Immuneering (IMRX) said Tuesday that new data from an ongoing phase 2a trial of its lead candidate IMM-1-104 in pancreatic cancer showed better overall response and disease control rates.

The updated results for IMM-1-104 combined with modified gemcitabine/nab-paclitaxel showed pancreatic cancer patients achieved an overall response rate of 43% and a disease control rate of 86%, compared with benchmarks of 23% and 48%, respectively, according to Immuneering Chief Executive Ben Zeskind.

In another combination arm with modified Folfirinox, all evaluable patients experienced target lesion shrinkage, including a 100% reduction, the company said.

As a monotherapy in second-line patients, IMM-1-104 demonstrated a partial response with 67% reduction in target lesions, according to Immuneering.

The drug was well-tolerated in both combination and monotherapy arms, the company said, adding it plans to expand the phase 2a trial in 2025 to include three new combination arms.

Shares of Immuneering surged past 91% in recent premarket activity Tuesday.